Product Program year 2025 Source: CMS Open Payments

Airsupra

Drug Respiratory

NDC 0310-9080-12

Open in the dashboard

General payments

$25,987,030

364,098 payments

Research payments

$130,587,985

1,929 payments

Through program year 2025, $25,987,030 in general payments and $130,587,985 in research payments were reported against Airsupra (Respiratory).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2025 General $11,350,180 165,266
2025 Research $90,430,222 1,230
2024 General $12,442,057 183,354
2024 Research $38,190,021 598
2023 General $2,194,794 15,478
2023 Research $1,967,742 101

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $25,977,584 364,082 payments
  2. AstraZeneca AB $6,588 2 payments
  3. AstraZeneca UK Limited $2,858 14 payments
Top recipients General payments · program year 2025
  1. Nina Ramirez Allergy & Immunology · Miami, FL $183,981 2% · 159 payments
  2. Cedric Franklin Rutland Critical Care Medicine · Riverside, CA $159,622 1% · 112 payments
  3. Autumn Burnette Allergy & Immunology · Washington, DC $155,354 1% · 115 payments
  4. Christopher Chao Family Medicine · Cary, NC $119,474 1% · 129 payments
  5. Susan Ratay Family Medicine · Ashtabula, OH $115,161 1% · 120 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Allergy & Immunology $2,735,097 25% · 1,238 practitioners
  2. Family Medicine $1,794,372 16% · 13,952 practitioners
  3. Pulmonary Disease Internal Medicine $1,518,477 14% · 2,544 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $1,217,564 11% · 13,578 practitioners
  5. Internal Medicine $979,978 9% · 8,565 practitioners

The top 5 of 161 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Florida $1,032,201 9% · 5,249 recipients
  2. California $1,017,611 9% · 3,753 recipients
  3. Texas $787,661 7% · 5,302 recipients
  4. Ohio $762,952 7% · 2,902 recipients
  5. New York $649,215 6% · 3,309 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

9,883

Prescriptions dispensed, refills included

Drug cost

$5,372,729

Paid at the pharmacy, in all

Prescribers

548

With 11 or more claims of it

Medicare Part D drugs matched to AIRSUPRA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Airsupra Albuterol Sulfate/Budesonide Same name 548 9,883 $5,372,729

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Calvin Ly Emergency Medicine CA 130 $69,551 None on record
Chuan Jiang Pulmonary Disease NY 119 $59,481 $254
Camil Kreit Family Practice TX 117 $58,820 $163
Dmitriy Yadgarov Pulmonary Disease NY 89 $39,208 None on record
Andrea Miller-Lari Allergy/ Immunology CA 78 $36,349 $115

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
364,098 general · 1,929 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record